Articles tagged with Migraines
A study of 55 patients found that 91% reported feeling hampered by headaches daily, and 37% experienced tension-type headaches several times a month. The total cost of all headache disorders in Denmark is approximately €74 million per million inhabitants per year.
Researchers found that overexpression of RAMP1 protein increases sensitivity and responsiveness to CGRP, a neuropeptide thought to cause migraines. The study suggests people who get migraines may have higher levels of RAMP1 than those who don't.
A study of 345 patients found that chronic dizziness was often caused by underlying psychiatric or neurologic conditions, with anxiety disorders accounting for 60% of cases. The research suggests that careful inquiry about key symptoms during evaluations can lead to more accurate diagnoses and targeted treatment recommendations.
A study of 1032 women with chronic headaches found that those with migraines were four times more likely to report major depression symptoms. Chronic headache sufferers also experienced high levels of pain-related symptoms, including low energy and trouble sleeping.
Research from Griffith University's Genomics Research Centre reveals that migraine significantly affects the lives of Australian men, causing poorer physical functioning and energy levels. Men with migraine often struggle to plan their lives due to unpredictable symptoms and apprehension, leading to reduced quality of life.
Researchers at OHSU School of Dentistry identify interaction between two proteins in nerve cells carrying pain information from the head and neck to the brain. This finding may help develop therapies for migraines and other craniofacial pain conditions.
A study of 4,181 adults found anxiety disorders independently associated with several physical conditions, increasing disability risk. Anxiety disorders were also linked to poorer quality of life in individuals with both conditions.
A recent study published in Neurology found that nearly 40% of children and teenagers with migraines no longer experience headaches 10 years later. Kids with a family history of migraines are more likely to still have migraines by adulthood.
Researchers at Harvard Medical School found increased thickness of two brain areas in people with migraine compared to healthy controls. The study used magnetic resonance imaging and identified structural differences that may explain visual processing problems during attacks.
A large study found that patients with IBS are 60% more likely to suffer from depression, migraine, or chronic pain compared to those without IBS. Individuals with IBS were also 40% more likely to experience depression and 60% more likely to suffer from migraine.
Researchers found that zolmitriptan nasal spray was effective in treating cluster headaches, providing pain relief to 50% of patients. The medication's quick absorption and minimal side effects make it a potential first-line treatment option for acute cluster headaches.
Migraines are more common in women than previously thought, and prevention is effective but often underused. The study reviews various stages of a woman's life, including childhood, reproductive years, pregnancy, and menopause, to provide guidance for physicians treating female migraine patients.
Women aged 45 years or older with migraines and aura have a higher risk of heart attack, stroke, angina, and death due to ischemic cardiovascular disease. In contrast, migraine without aura was not associated with an increased risk of cardiovascular events.
Researchers at Ohio State University Medical Center have developed a device that effectively eliminates migraine pain by targeting the aura phase. The TMS device sends an electric current to the brain, interrupting the neural disturbances that signal the onset of migraines.
Researchers developed a new PET scan technique to detect Alzheimer's disease plaques and tangles, while the ApoE gene was found to significantly increase stroke risk in Asian populations. Foramen ovale closure surgery also showed promise in reducing migraine headaches in patients with an open heart opening.
Researchers at the University of Texas at Austin have discovered a link between estrogen, progesterone, and allergic responses in women. High levels of IgE antibodies against these hormones are associated with symptoms such as premenstrual asthma, menstrual migraines, and fibromyalgia.
The MIST trial studied patients with severe, frequent migraines and a medium-to-large PFO, randomly assigning them to PFO closure or sham intervention. Results showed promise for PFO closure as a treatment option for relieving migraines.
A clinical trial found that acupuncture reduced migraine days equally to standard therapy, with no difference between real and sham acupuncture. The study's results are surprising, as the underlying mechanisms are unknown, but suggest that efficacy is more important than understanding treatment mechanisms.
Cyclical vomiting syndrome affects adults with recurring episodes of incapacitating nausea and vomiting, often triggered by panic attacks. The disorder originates in the central nervous system, not the abdomen, and can be challenging to diagnose due to its unique clinical pattern.
Researchers found botulinum toxin type A significantly reduced pain in all 13 patients with trigeminal neuralgia within 10 days of injection. By 60 days, four patients became medication-free and others reduced their medication use by over 50%.
Researchers have made significant progress in understanding the genetic mutations that cause familial migraines. By studying how these mutations affect the sodium pump, a crucial cellular mechanism, Dr. Rhoda Blostein and her team identified key changes that disrupt its operation, leading to migraine development.
A University of Pittsburgh study published in the Journal of Neurosurgery found that athletes with post-traumatic migraine (PTM) after a concussion experienced increased neurocognitive function impairment. This suggests that clinicians should exercise caution when managing concussed athletes with PTM.
A randomized controlled trial of 302 patients with migraines found that acupuncture and sham acupuncture resulted in similar reductions in headache frequency. While acupuncture was associated with a reduction in migraine headaches compared to no treatment, the effects were comparable to those observed with sham acupuncture.
A recent study conducted in Norway found that bright Arctic light can trigger migraines in women with aura. The research revealed that nearly half of those with migraine with aura experienced more frequent attacks during the summer light season than during the polar winter season.
Researchers found that pretreating with DHE can prevent migraines from progressing to debilitating sensitization. This breakthrough suggests that more patients can benefit from standard treatment using intravenous DHE.
People with migraine are 43% more likely to be smokers and have high cholesterol, while those with aura symptoms are more likely to have high blood pressure and history of stroke or heart disease. The study suggests a shared predisposition toward both conditions.
Researchers found that women who experience vision loss during a migraine are 70% more likely to have a stroke. Migraines without visual symptoms do not significantly increase stroke risk. The study's findings suggest that women with migraines and aura should address other stroke risk factors, such as smoking.
The study found that surgical treatment significantly reduced migraine frequency, intensity, and duration for 92% of patients. This led to a notable decrease in missed workdays from 4.4 to 1.2 days per month, saving employees approximately $6,687 annually.
A study by Dr. Kathryn M. Rose found that individuals with migraines or other severe headaches were three times more likely to report chest pain compared to those without such conditions. However, the study did not find a significant association between headaches and coronary heart disease.
The new guidelines provide a comprehensive review of related studies on the most effective medicines to treat migraine attacks and prevent attacks in children with frequent migraines. However, the authors found insufficient evidence to recommend the use of certain preventive agents, such as cyproheptadine and amitriptyline.
A new Italian study found that women with endometriosis have a significantly higher prevalence of migraine, but no link to attack frequency or pain intensity. The study also suggests that investigating headaches in women with endometriosis is crucial for proper diagnosis and treatment.
The American Academy of Neurology has updated its diagnostic standard for headaches, adding new subtypes and disorders. The revised criteria provide a clearer framework for diagnosing and treating various types of primary and secondary headaches.
A new study shows that Frovatriptan is effective in preventing Menstrual Associated Migraine (MAM) headaches, significantly reducing their severity, duration, and functional impairment. The medication reduces MAM incidence by up to 50% and is well-tolerated with minimal side effects.
Research reveals that women are 25% more likely to experience migraines before menstruation and that severe attacks often occur during pre- and post-menstruation intervals. Medication frovatriptan shows promise in preventing menstrually-related migraines, with over half of patients experiencing no migraine attacks.
A new clinical trial demonstrates that treating migraine with Relpax during mild pain provides greater efficacy than waiting for pain to become more severe. Patients who treated early experienced significantly higher two-hour pain-free rates compared to those who waited.
A study of 42 people found that those taking CoQ10 had significantly fewer migraine attacks than those taking a placebo, with 48% experiencing half as many attacks. The only side effect reported was an allergic skin rash in one patient.
Research found a 50% increased risk of total stroke and 70% increased risk of ischemic stroke in women with migraine with aura, compared to those without. High cholesterol levels were also associated with an increased risk of ischemic stroke.
A 26-week study found that topiramate significantly reduced the frequency of migraines in patients taking 100 or 200 milligrams per day. Improvements were observed within the first month of treatment, with 35.9% to 54.0% of patients experiencing a 50% or more reduction in migraine frequency.
A recent study found that sumatriptan nasal spray provides good to excellent headache relief in over three-quarters of children with chronic migraines. The off-label use of the medication has been shown to be effective and safe for treating this condition, especially when other treatments have failed.
Researchers created a mouse model for migraines to study debilitating headaches. The FHM mouse showed increased calcium channel activation and susceptibility to cortical spreading depression (CSD), suggesting hyperexcitability in the brain may trigger pain.
A 26-week study found that topiramate significantly reduced monthly migraine frequency (-2.1 and -2.4 mg/d) and days with migraines compared to placebo. The medication also decreased rescue medication use, providing improved treatment outcomes for patients.
A study found that people with migraines have a higher risk of developing brain infarcts and white matter lesions, especially in the cerebellar region. Women with migraine also had twice the risk for deep WMLs compared to controls.
The American Medical Association highlights the growing importance of migraine prevention, which can reduce attack frequency and severity. Preventive therapy has shown dramatic results in patients transitioning from acute to combination acute and preventive therapy.
A study found that ID Migraine screener is reliable in detecting migraines in undiagnosed patients. The three-question survey showed a high accuracy rate of 93% for diagnosing migraines.
A nationwide study found that frovatriptan succinate prevented menstrually associated migraines (MAM) in as many as half the women evaluated. The drug significantly reduced MAM severity and duration, as well as patients' functional impairment and use of rescue medications.
Patients with recurring migraines recorded non-headache symptoms in an electronic diary for three months, revealing a consistent pattern of symptoms leading up to the headache. The study suggests that learning to recognize these symptoms can help patients prevent or minimize their migraines, providing a new treatment option.
A community study of 400 patients with various pain types found that Keppra was well-tolerated and provided significant pain relief. The medication was effective in treating a range of conditions, including migraine headaches, nerve pain, and diabetic pain.
According to Dr. Robert Kaniecki, a University of Pittsburgh neurologist, migraine headaches are often underdiagnosed, with over 50% of patients being mislabeled as having 'sinus headache' or 'tension headache'. This can lead to excessive prescriptions for antibiotics and decongestants, contributing to antibiotic resistance.
A 12-week study shows candesartan cilexetil significantly reduces headache days and sick leave in patients with migraines. The medication's benefits are associated with good tolerability, making it an exciting alternative to current therapies.
The American College of Physicians and the American Academy of Family Physicians have released new guidelines for treating migraines, recommending immediate treatment with NSAIDs or triptans, as well as managing nausea and vomiting symptoms. The guidelines also emphasize the importance of patient involvement in charting migraines and i...
The Lancet neurology reviews research on migraine genetics, highlighting the challenges of identifying genes involved in the disorder. The article also examines the implications of private diagnostic testing without physician support, sparking debate about its role in advancing treatment options for neurological diseases.
A study by the University of Michigan found that migraine headaches affect 18% of women and 6% of men, resulting in significant lost productivity costs for employers. Employers can reduce these costs by providing education, preventive services, and direct treatment within the workplace.
Researchers have identified a mouse model to investigate triggers of episodic neurological disorders, including common migraine and periodic paralysis. Two drugs, nimodipine and MK801, have been found to prevent attacks in mice, providing a potential new approach to understanding and treating these conditions.
Researchers at Ohio University found that a behavioral therapy program reduced migraine frequency and severity in teens by 80%, with no medication required. The study suggests an alternative approach to treating migraines in children and teens.
A study presented at the American Academy of Neurology's annual meeting found that cortical spreading depression, a brain event linked to migraines, affects specific genes. Researchers identified two peptides influencing blood vessel activity and pain control, which may be related to menstrual migraine attacks.
A recent study found that migraine prevalence in the US has remained stable over the past decade, with many sufferers relying on over-the-counter medications. The study suggests that millions of people could benefit from proper medical attention, which can lead to more effective treatment and improved quality of life.
Researchers have found that treating inflammation in the trochlea tendon can relieve headache pain associated with migraines. In a study of five women with trochleitis, steroid injections produced relief from ocular pain and associated migraine symptoms within 48 to 72 hours.
Researchers discovered a link between inflamed tender areas above upper molar teeth and headaches. A new treatment involves chilling the area to reduce swelling, eliminating pressure on nerves. The anti-inflammatory gel was found to be more effective than existing medications in reducing headache burden and analgesic use.
A meta-analysis of 53 controlled clinical trials involving over 24,000 patients found that 10mg rizatriptan, 80mg eletriptan, and 12.5mg almotriptan showed better efficacy and consistency compared to sumatriptan. The results suggest that physicians need a variety of triptans in their repertoire to best treat patients with migraine.
A study found that biofeedback-assisted relaxation training techniques significantly reduced headache frequency and severity in children with migraines. The treatment improved school attendance by 85% of parents' reports, demonstrating its potential as a complementary therapy for managing migraines in children.